ABUS vs CE
Arbutus Biopharma Corp (ABUS) versus Celanese Corporation (CE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Celanese Corporation (CE) is a chemicals company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CE revenue for 2024-12-31 was $10.28B. Net income was -$1.51B. Revenue was down 6.0% from 2023-12-31 to 2024-12-31. CE currently screens at market cap $5.92B.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CE currently screens at market cap $5.92B.
Not investment advice. Open the ABUS and CE stock pages for the full models.
Not investment advice.